top of page

Azome Therapeutics:

Developing a compelling narrative for potential investors


Azome Therapeutics is an early-stage drug discovery company focused on advancing treatment of severe inflammatory diseases.  The company’s RHAMM-antagonist platform blocks NLRP3 inflammasome activation, and its lead drug candidate, AZM-152, has demonstrated significant preclinical potential in a number of severe inflammatory diseases, including several that have significant unmet needs.


Since mid 2023, NVision has been working closely with Azome leadership to develop a compelling narrative for potential investors.  This has included new branding, a new website, and presentation materials as well as the development and management of an ongoing and consistent newsflow of information, designed to differentiate the company and its core platform technology.

bottom of page